ZANOTERONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H32N2O3S
Molecular Weight	416.577
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC5=NN(C=C5C[C@]34C)S(C)(=O)=O)[C@@H]1CC[C@@]2(O)C#C

InChI

InChIKey=MHDDZDPNIDVLNK-ZGIWMXSJSA-N

InChI=1S/C23H32N2O3S/c1-5-23(26)11-9-19-17-7-6-16-12-20-15(14-25(24-20)29(4,27)28)13-21(16,2)18(17)8-10-22(19,23)3/h1,14,16-19,26H,6-13H2,2-4H3/t16-,17+,18-,19-,21-,22-,23-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2615358 | https://www.ncbi.nlm.nih.gov/pubmed/7543598

Zanoterone (or Win 49596), a steroidal androgen receptor antagonist was studied for the treatment of benign prostatic hyperplasia. The drug did not demonstrate a favorable risk-to-benefit profile and further development was stopped.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Androgen receptor 42 Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2615358	Antagonist 2849

PubMed

Title	Date	PubMed
The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. The Zanoterone Study Group.	1995-09	7543598
Studies on the mechanism of action of Win 49596: a steroidal androgen receptor antagonist.	1989-12	2615358

Patents

Sample Use Guides

In Vivo Use Guide

Zanoterone (100 to 800 mg.) versus placebo was studied in 463 patients with benign prostatic hyperplasia

Route of Administration: Oral

Name

Type

Language

WIN 49,596

Preferred Name

English

ZANOTERONE

Official Name

English

WIN-49596

Code

English

zanoterone [INN]

Common Name

English

ZANOTERONE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C242